Extended Data Fig. 3: Immune-profiling of tumors in Pglyrp1-deficient mice.

(a) Pglyrp1^−/− mouse validation. Relative expression (RE) of Pglyrp1 transcript in WT, Pglyrp1^−/+, and Pglyrp1^−/− CD8⁺ T cells from the spleen by qPCR (n = 2-3). The expression is depicted as relative to WT cells. The bar indicates the mean. (b–d) Analysis of the immune system in the colon of 7-week-old Pglyrp1^−/− mice and WT littermates by flow cytometry (n = 3). General immune system composition (b), and intra-cellular cytokine staining in CD4⁺ T cells (c) and CD8⁺ T cells (d) are displayed. (e, f) B16-OVA tumors were implanted into WT and Pglyrp1^−/− mice (n = 7). (e) Mean tumor growth and (f) tumor sizes on day 16 are shown. (g) MC38-OVA tumors were implanted into WT and Pglyrp1^−/− mice and mice were treated with anti-PD-1 antibody on days 6, 8, and 10 post tumor-implantation. The control group included WT mice injected with control immunoglobulin (Rat IgG2a). (h) Relative expression of Pglyrp1 transcript in different immune populations isolated from MC38-OVA tumors grown in WT mice by qPCR (n = 4). (i) Frequency of different immune populations in MC38-OVA tumors grown in WT and Pglyrp1^−/− mice (n = 9) by flow cytometry. In (b-i) data are presented as the mean with ±SEM. Unpaired two-tailed t-tests were performed. NS, not significant.